Skip to main content
. Author manuscript; available in PMC: 2021 Feb 1.
Published in final edited form as: Prostate. 2019 Nov 15;80(2):133–145. doi: 10.1002/pros.23925

FIGURE 3.

FIGURE 3

RELA mediates IL-1 repression of AR. A, RT-qPCR and B, Western blot analysis and densitometry were performed for LNCaP, C4-2, and C4-2B cells transfected with 70 nM of nontargeting or RELA siRNA (Dharmacon) for 1 day followed by treatment with vehicle control (Veh), IL-1α, IL-1β for 2 days. LNCaP cells were treated with 0.5 ng/mL IL-1, and C4-2 and C4-2B cells were treated with 25 ng/mL IL-1. RELA siRNA attenuates IL-1 downregulation of AR and PSA mRNA and protein, and attenuates IL-1 upregulation of SOD2 mRNA and protein. mRNA fold change is normalized to the vehicle control. Error bars indicate ±SD of three biological replicates; *P ≤ .05, **P ≤ .005, ***P ≤ .0005. AR, androgen receptor; IL, interleukin; mRNA, messenger RNA; PSA, prostate-specific antigen; RT-qPCR, reverse-transcription quantitative polymerase chain reaction; SD, standard deviation; siRNA, small interfering RNA; SOD2, superoxide dismutase 2